Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts

Savara Inc (NASDAQ:SVRA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $9.86.

Several analysts have issued reports on SVRA shares. HC Wainwright dropped their target price on Savara from $10.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. Wells Fargo & Company assumed coverage on Savara in a report on Friday, December 20th. They issued an "overweight" rating and a $8.00 target price for the company. Evercore ISI reiterated an "in-line" rating and set a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, JMP Securities reiterated a "market outperform" rating and set a $9.00 price target on shares of Savara in a report on Thursday, December 19th.

Savara Price Performance

NASDAQ SVRA traded down $0.13 during mid-day trading on Friday, hitting $2.75. The stock had a trading volume of 1,386,054 shares, compared to its average volume of 849,312. The firm's 50 day moving average is $3.17 and its 200 day moving average is $3.79. Savara has a twelve month low of $2.60 and a twelve month high of $5.70. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock has a market capitalization of $471.96 million, a price-to-earnings ratio of -6.40 and a beta of 0.68.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). Equities research analysts forecast that Savara will post -0.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Matthew Pauls sold 54,702 shares of the business's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares in the company, valued at $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph S. Mccracken bought 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The shares were acquired at an average price of $2.95 per share, with a total value of $59,000.00. Following the purchase, the director now owns 210,837 shares of the company's stock, valued at $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 5.13% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Savara

Institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd increased its position in Savara by 289.1% during the second quarter. XTX Topco Ltd now owns 41,059 shares of the company's stock worth $165,000 after buying an additional 30,508 shares during the period. Profund Advisors LLC acquired a new position in Savara during the second quarter worth approximately $105,000. Marshall Wace LLP increased its position in Savara by 420.0% during the second quarter. Marshall Wace LLP now owns 304,700 shares of the company's stock worth $1,228,000 after buying an additional 246,107 shares during the period. Squarepoint Ops LLC acquired a new position in Savara during the second quarter worth approximately $452,000. Finally, The Manufacturers Life Insurance Company increased its position in Savara by 14.9% during the second quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company's stock worth $166,000 after buying an additional 5,335 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.